IL139210A - Pharmaceutical composition containing a macrolide compound - Google Patents

Pharmaceutical composition containing a macrolide compound

Info

Publication number
IL139210A
IL139210A IL13921099A IL13921099A IL139210A IL 139210 A IL139210 A IL 139210A IL 13921099 A IL13921099 A IL 13921099A IL 13921099 A IL13921099 A IL 13921099A IL 139210 A IL139210 A IL 139210A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
composition containing
macrolide compound
macrolide
compound
Prior art date
Application number
IL13921099A
Other languages
English (en)
Other versions
IL139210A0 (en
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of IL139210A0 publication Critical patent/IL139210A0/xx
Publication of IL139210A publication Critical patent/IL139210A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13921099A 1998-04-27 1999-04-26 Pharmaceutical composition containing a macrolide compound IL139210A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11727198 1998-04-27
PCT/JP1999/002237 WO1999055332A1 (fr) 1998-04-27 1999-04-26 Compositions medicinales

Publications (2)

Publication Number Publication Date
IL139210A0 IL139210A0 (en) 2001-11-25
IL139210A true IL139210A (en) 2005-11-20

Family

ID=14707636

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13921099A IL139210A (en) 1998-04-27 1999-04-26 Pharmaceutical composition containing a macrolide compound

Country Status (24)

Country Link
US (2) US6673808B1 (tr)
EP (1) EP1074255B1 (tr)
JP (1) JP3732525B2 (tr)
KR (1) KR100406823B1 (tr)
CN (1) CN1161117C (tr)
AR (1) AR018330A1 (tr)
AT (1) ATE363275T1 (tr)
AU (1) AU749475B2 (tr)
BR (1) BR9910336A (tr)
CA (1) CA2326222C (tr)
DE (1) DE69936195T2 (tr)
ES (1) ES2284248T3 (tr)
HK (1) HK1038884B (tr)
HU (1) HUP0104452A3 (tr)
ID (1) ID29262A (tr)
IL (1) IL139210A (tr)
NO (1) NO20005399D0 (tr)
NZ (1) NZ507345A (tr)
PL (1) PL343627A1 (tr)
RU (1) RU2203058C2 (tr)
TR (1) TR200003108T2 (tr)
TW (1) TW565461B (tr)
WO (1) WO1999055332A1 (tr)
ZA (1) ZA200005378B (tr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
BR0011225A (pt) * 1999-04-30 2002-03-19 Sucampo Ag Agente para tratar de olhos secos, seu método e uso
MX368013B (es) * 2001-02-19 2019-09-13 Novartis Ag Tratamiento de cáncer.
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
WO2006001251A1 (ja) * 2004-06-24 2006-01-05 Kowa Co., Ltd. アトルバスタチン外用剤組成物
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
EP1904056B1 (en) 2005-07-18 2009-04-29 Minu, L.L.C. Use of a macrolide to restore corneal sensation
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
CN102176913B (zh) * 2008-10-08 2014-08-13 高田制药株式会社 外用的他克莫司制剂
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
JP2011102260A (ja) * 2009-11-11 2011-05-26 Takada Seiyaku Kk タクロリムス外用剤
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
US20130317053A1 (en) * 2011-01-31 2013-11-28 Osaka University Externally-used drug for treating skin disorder and method for producing same
US20230056335A1 (en) * 2020-01-24 2023-02-23 Nobelpharma Co., Ltd. Topical formulation containing rapamycin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454113A (en) * 1982-09-21 1984-06-12 Scm Corporation Stabilization of oil and water emulsions using polyglycerol esters of fatty acids
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
ES2099112T3 (es) * 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
TW213418B (tr) * 1991-05-02 1993-09-21 Kuko Seiyaku Kk
JPH06128148A (ja) * 1992-04-30 1994-05-10 Dotsuto:Kk 皮膚外用剤
JP2523428B2 (ja) * 1992-12-04 1996-08-07 エスエス製薬株式会社 消炎鎮痛ゲル製剤
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
BR9509530A (pt) * 1994-10-26 1997-10-14 Novartis Ag Composições farmacêuticas
RU2156127C2 (ru) 1995-12-28 2000-09-20 Еситоми Фармасьютикал Индустриз, Лтд. Препарат местного применения для иммуносупрессии и лечения аутоиммунных или аллергических заболеваний
CZ283516B6 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
CN1259053A (zh) * 1997-04-11 2000-07-05 藤泽药品工业株式会社 药物组合物

Also Published As

Publication number Publication date
CA2326222A1 (en) 1999-11-04
NO20005399L (no) 2000-10-26
NZ507345A (en) 2002-12-20
ATE363275T1 (de) 2007-06-15
CN1307475A (zh) 2001-08-08
WO1999055332A8 (fr) 2000-02-17
EP1074255B1 (en) 2007-05-30
RU2203058C2 (ru) 2003-04-27
AR018330A1 (es) 2001-11-14
NO20005399D0 (no) 2000-10-26
EP1074255A1 (en) 2001-02-07
US20020061907A1 (en) 2002-05-23
EP1074255A4 (en) 2002-02-13
TW565461B (en) 2003-12-11
IL139210A0 (en) 2001-11-25
AU3537299A (en) 1999-11-16
KR100406823B1 (ko) 2003-11-21
BR9910336A (pt) 2001-09-25
HK1038884B (zh) 2005-05-06
HK1038884A1 (en) 2002-04-04
TR200003108T2 (tr) 2001-02-21
US6673808B1 (en) 2004-01-06
PL343627A1 (en) 2001-08-27
ZA200005378B (en) 2002-08-23
CA2326222C (en) 2008-09-23
HUP0104452A3 (en) 2004-05-28
ES2284248T3 (es) 2007-11-01
KR20010042589A (ko) 2001-05-25
HUP0104452A2 (hu) 2002-03-28
CN1161117C (zh) 2004-08-11
US6586444B2 (en) 2003-07-01
DE69936195D1 (de) 2007-07-12
AU749475B2 (en) 2002-06-27
JP3732525B2 (ja) 2006-01-05
DE69936195T2 (de) 2007-09-13
ID29262A (id) 2001-08-16
WO1999055332A1 (fr) 1999-11-04

Similar Documents

Publication Publication Date Title
IL139210A0 (en) A pharmaceutical composition containing a macrolide compound
GB9817118D0 (en) Pharmaceutical compounds
IL187526A0 (en) Pharmaceutical compositions containing an a?? fragment
HU9901606D0 (en) Pharmaceutical compositions
IL193245A0 (en) Pharmaceutical compositions containing an a?? fragment
GB9817623D0 (en) Pharmaceutical compounds
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
GB9827996D0 (en) Pharmaceutical Compositions
HUP0103507A3 (en) Pharmaceutical compositions comprising 2-quinolones
GB9810886D0 (en) Pharmaceutical compounds
PT1466615E (pt) Composição farmacêutica
AU4143999A (en) Oral composition comprising capsules
IL141876A0 (en) A pharmaceutical composition containing fetuin
PL343769A1 (en) Pharmaceutical composition
GB9809213D0 (en) Pharmaceutical compositions
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
HUP0102894A3 (en) A substituted triazolo-pyridazine derivative, pharmaceutical compositions containing them
AU6370299A (en) Pharmaceutical compositions containing tetrahydroisoquinoline compounds
IL142534A0 (en) Pharmaceutical compositions containing an antigen-adjuvent
AU3057099A (en) A drug composition containing sodium pravastatin
GB9800750D0 (en) Pharmaceutical compound
GB9823847D0 (en) Pharmaceutical compounds
GB9823845D0 (en) Pharmaceutical compounds
EP1124557A4 (en) PHARMACEUTICAL COMPOSITION
HK1030552A1 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FF Patent granted
HC Change of name of proprietor(s)
MM9K Patent not in force due to non-payment of renewal fees